Sometimes a clinical trial misses the mark but still tells you something useful. That's the story Aclaris Therapeutics Inc. (NASDAQ:ACRS) is pitching to investors after its Phase 2 atopic dermatitis study came up short on efficacy. CEO Neal Walker said Monday the clinical-stage biopharma will keep its core development priorities intact despite the miss, and he's not wavering on the bigger picture: advancing oral kinase inhibitors and bispecific antibody programs toward major clinical and regulatory milestones throughout 2027.
Aclaris Therapeutics Stock Falls 13% After Eczema Drug Misses Endpoints, But CEO Isn't Backing Down
Get Aclaris Therapeutics Alerts
Weekly insights + SMS alerts
Bosakitug Misses Endpoints But Shows Target Engagement
Aclaris reported topline data from the Phase 2 ADMIRATION trial evaluating bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, in patients with moderate-to-severe atopic dermatitis. The study failed to meet its primary or secondary efficacy goals. Not great. But patients generally tolerated the treatment well, and pharmacodynamic data revealed strong TSLP target engagement alongside the downregulation of key immune activation biomarkers, including Th1, Th2, and Th17. In plain English: the drug hit its biological target, even if the clinical scorecard didn't cooperate. That's the kind of detail that can keep a program alive.
Aclaris Launches Phase 2b Modzatinib Trial
Alongside the readout, Aclaris initiated its Phase 2b ALPHA trial of modzatinib (ATI-2138) for moderate-to-severe lichen planus (LP). LP is a chronic inflammatory, autoimmune condition that causes an immune system attack against cells in the skin, hair, nails, and mucous membranes. It leads to painful oral erosions, genital lesions, permanent scarring, and hair loss, while oral LP carries a malignancy risk. The U.S. Food and Drug Administration previously granted Fast Track Designation to modzatinib for this chronic, CD8 cytotoxic T cell-driven inflammatory disease.
The ALPHA study will evaluate two dose levels of modzatinib against a placebo in roughly 100 participants whose biopsy-proven disease resists topical therapies. Researchers will enroll patients with oral erosive LP in the initial cohort.
Dual Mechanism And Upcoming Pipeline Milestones
Modzatinib, a potential first-in-class oral therapy, inhibits both ITK and JAK3 to disrupt LP pathology at two points. ITK inhibition blocks upstream T-cell receptor signaling to reduce T-cell activation, cytotoxicity, and inflammatory cytokines, while JAK3 inhibition blocks downstream cytokine signaling to curb T-cell proliferation and survival. It's a two-pronged approach that could matter in a disease where options are limited.
CEO Walker noted that Aclaris also completed IND-enabling studies for its oral ITK inhibitor ATI-9494 and plans to submit the IND this quarter. Additionally, the company aims to launch a Phase 2b trial of its anti-TSLP/IL-4Rα bispecific antibody, ATI-052, in eosinophilic esophagitis during the first quarter of 2027.
ACRS Price Action: Aclaris Therapeutics shares were down 13.52% at $3.39 during premarket trading on Monday, according to market data.
More News

Jensen Huang Once Bragged He Never Got Fired. This Week He Resigned From Nvidia.

Washington Slams China's AI Chip Back Door Shut, and Tech Stocks Lose $960 Billion

Bitcoin, Ethereum, XRP Brace for Fed-Packed Week After $1.49B ETF Exodus

Wall Street Dumped Chips for Coca-Cola at the Fastest Clip Since 2001

Home Depot Earnings Could Swing $15.5 Billion: The Options Market's Volatility Countdown

Nvidia's China Headache Is Now AMD's Problem Too

Bernie Sanders to Big Tech: Your $3 Trillion AI Debt Is a 'High-Stakes Gamble' — and Taxpayers Won't Be Your Safety Net

Supermicro Slides 6% as DOJ China Probe and Nvidia CEO Shakeup Spook AI Hardware Investors
Get Aclaris Therapeutics Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Jensen Huang Once Bragged He Never Got Fired. This Week He Resigned From Nvidia.

Washington Slams China's AI Chip Back Door Shut, and Tech Stocks Lose $960 Billion

Bitcoin, Ethereum, XRP Brace for Fed-Packed Week After $1.49B ETF Exodus

Wall Street Dumped Chips for Coca-Cola at the Fastest Clip Since 2001

Home Depot Earnings Could Swing $15.5 Billion: The Options Market's Volatility Countdown

Nvidia's China Headache Is Now AMD's Problem Too

Bernie Sanders to Big Tech: Your $3 Trillion AI Debt Is a 'High-Stakes Gamble' — and Taxpayers Won't Be Your Safety Net






